(Q33378789)

26 July 2017

title

A phase II study of pemetrexed in patients with advanced hepatocellular carcinoma (English)

1 reference

26 July 2017

Allen L Cohn

1

1 reference

26 July 2017

J William Myers

2

1 reference

26 July 2017

Steven Mamus

3

1 reference

26 July 2017

Charles Deur

4

1 reference

26 July 2017

Steven Nicol

5

1 reference

26 July 2017

Karen Hood

6

1 reference

26 July 2017

Muhammad M Khan

7

1 reference

26 July 2017

Des Ilegbodu

8

1 reference

26 July 2017

Lina Asmar

9

1 reference

26 July 2017

publication date

28 February 2008

1 reference

Investigational New Drugs

26 July 2017

published in

1 reference

26 July 2017

volume

26

1 reference

26 July 2017

issue

4

1 reference

26 July 2017

page(s)

381-386

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-008-9124-5

26 July 2017

exact match

0 references

cites work

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

The potential role of pemetrexed in gastrointestinal cancer

1 reference

12 December 2020

Pemetrexed in advanced colorectal cancer

1 reference

12 December 2020

Hepatocellular carcinoma: current management and future trends.

1 reference

12 December 2020

Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: a phase II study

1 reference

12 December 2020

Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma

1 reference

12 December 2020

Glutamyl hydrolase and the multitargeted antifolate LY231514.

1 reference

12 December 2020

Pemetrexed (Alimta, LY231514) demonstrates clinical activity in chemonaive patients with cervical cancer in a phase II single-agent trial

1 reference

12 December 2020

Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer

1 reference

12 December 2020

Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies.

1 reference

12 December 2020

Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma

1 reference

12 December 2020

A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer

1 reference

12 December 2020

Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy.

1 reference

12 December 2020

Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy

1 reference

12 December 2020

Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum

1 reference

12 December 2020

Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay.

1 reference

12 December 2020

Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma

1 reference

12 December 2020

Emerging approaches in hepatocellular carcinoma.

1 reference

12 December 2020

10.1007/S10637-008-9124-5

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

1046184818

0 references

1 reference